Calidi Biotherapeutics Inc. (NYSE MKT:CLDI) — Market Cap & Net Worth
Market Cap & Net Worth: Calidi Biotherapeutics Inc. (CLDI)
Calidi Biotherapeutics Inc. (NYSE MKT:CLDI) has a market capitalization of $2.68 Million ($2.68 Million) as of May 26, 2026. Listed on the NYSE MKT stock exchange, this USA-based company holds position #29555 globally and #5881 in its home market, demonstrating a -7.32% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Calidi Biotherapeutics Inc.'s stock price $0.18 by its total outstanding shares 15228625 (15.23 Million). Analyse Calidi Biotherapeutics Inc. cash flow conversion to see how efficiently the company converts income to cash.
Calidi Biotherapeutics Inc. Market Cap History: 2021 to 2026
Calidi Biotherapeutics Inc.'s market capitalization history from 2021 to 2026. Data shows growth from $15.23K to $2.68 Million (211.07% CAGR).
Calidi Biotherapeutics Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Calidi Biotherapeutics Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.34x
Calidi Biotherapeutics Inc.'s market cap is 0.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2021 | $15.23K | $449.00K | -$10.93 Million | 0.03x | N/A |
| 2022 | $15.23K | $45.00K | -$25.43 Million | 0.34x | N/A |
Competitor Companies of CLDI by Market Capitalization
Companies near Calidi Biotherapeutics Inc. in the global market cap rankings as of May 26, 2026.
Key companies related to Calidi Biotherapeutics Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.28 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #417 globally with a market cap of $65.82 Billion USD.
- argenx NV ADR (NASDAQ:ARGX): Ranked #579 globally with a market cap of $45.97 Billion USD.
- UCB S.A. UNSP.ADR 1/2 (F:UNC0): Ranked #599 globally with a market cap of $44.84 Billion USD ( €38.35 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.28 Billion | $434.52 |
| #417 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $65.82 Billion | $638.88 |
| #579 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
| #599 | UCB S.A. UNSP.ADR 1/2 | F:UNC0 | $44.84 Billion | €120.00 |
Calidi Biotherapeutics Inc. Historical Marketcap From 2021 to 2026
Between 2021 and today, Calidi Biotherapeutics Inc.'s market cap moved from $15.23K to $ 2.68 Million, with a yearly change of 211.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.68 Million | -84.96% |
| 2025 | $17.82 Million | +1.74% |
| 2024 | $17.51 Million | -92.38% |
| 2023 | $229.95 Million | +1509900.00% |
| 2022 | $15.23K | 0.00% |
| 2021 | $15.23K | -- |
End of Day Market Cap According to Different Sources
On May 25th, 2026 the market cap of Calidi Biotherapeutics Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.68 Million USD |
| MoneyControl | $2.68 Million USD |
| MarketWatch | $2.68 Million USD |
| marketcap.company | $2.68 Million USD |
| Reuters | $2.68 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Calidi Biotherapeutics Inc.
Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast ca… Read more